Boehringer Ingelheim Pharmaceuticals, Inc., the US Subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 47 countries with approximately 39,800 employees. The company is committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine